| NASDAQ (usa) |
|
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
![]() |
7487.96 | -5.12 | -0.07% |
| DAX (german) |
|
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Foresee Pharmaceuticals Co. Ltd. (TWO: 6576)
6576 Technical Analysis
1.5
| As on 14th Nov 2025 6576 STOCK Price closed @ 85.20 and we RECOMMEND Buy for LONG-TERM with Stoploss of 80.24 & Sell for SHORT-TERM with Stoploss of 87.53 we also expect STOCK to react on Following IMPORTANT LEVELS. |
6576STOCK Price
| Open | 85.20 | Change | Price | % |
| High | 85.20 | 1 Day | 7.70 | 9.94 |
| Low | 85.20 | 1 Week | 7.50 | 9.65 |
| Close | 85.20 | 1 Month | 3.00 | 3.65 |
| Volume | 847310 | 1 Year | -9.10 | -9.65 |
| 52 Week High 99.60 | 52 Week Low 57.90 | ||||
TWO Taiwan Most Active Stocks
| 1815 | 89.00 | -3.58% |
| 6173 | 67.80 | 0.44% |
| 5340 | 68.20 | 6.40% |
| 6265 | 20.90 | 7.46% |
| 5328 | 20.95 | -1.87% |
| 8111 | 68.50 | -1.44% |
| 8043 | 64.20 | 9.93% |
| 3624 | 49.60 | 6.21% |
| 3236 | 26.10 | 0.00% |
| 5351 | 44.20 | -3.18% |
TWO Taiwan Top Gainers Stocks
TWO Taiwan Top Losers Stocks
| 6576 Daily Charts |
6576 Intraday Charts |
Whats New @ Bazaartrend |
6576 Free Analysis |
|
|
6576 Important Levels Intraday
| RESISTANCE | 85.20 |
| RESISTANCE | 85.20 |
| RESISTANCE | 85.20 |
| RESISTANCE | 85.20 |
| RESISTANCE | 85.20 |
| RESISTANCE | 85.20 |
| RESISTANCE | 85.20 |
| RESISTANCE | 85.20 |
6576 Forecast November 2025
| 4th UP Forecast | 122.01 |
| 3rd UP Forecast | 110.2 |
| 2nd UP Forecast | 102.91 |
| 1st UP Forecast | 95.61 |
| 1st DOWN Forecast | 74.79 |
| 2nd DOWN Forecast | 67.49 |
| 3rd DOWN Forecast | 60.2 |
| 4th DOWN Forecast | 48.39 |
6576 Weekly Forecast
| 4th UP Forecast | 98.30 |
| 3rd UP Forecast | 94.10 |
| 2nd UP Forecast | 91.50 |
| 1st UP Forecast | 88.91 |
| 1st DOWN Forecast | 81.49 |
| 2nd DOWN Forecast | 78.90 |
| 3rd DOWN Forecast | 76.30 |
| 4th DOWN Forecast | 72.10 |
6576 Forecast2025
| 4th UP Forecast | 168.64 |
| 3rd UP Forecast | 141.88 |
| 2nd UP Forecast | 125.34 |
| 1st UP Forecast | 108.8 |
| 1st DOWN Forecast | 61.6 |
| 2nd DOWN Forecast | 45.06 |
| 3rd DOWN Forecast | 28.52 |
| 4th DOWN Forecast | 1.76 |
Foresee Pharmaceuticals Co. Ltd. ( TWO Taiwan Symbol : 6576 )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
6576 Other Details
| Segment | EQ | |
| Market Capital | 10111431680.00 | |
| Sector | Healthcare | |
| Industry | Drug Manufacturers-Specialty & Generic | |
| Offical website | > echo $website ; ?> | |
6576 Address
![]() |
||
6576 Latest News
6576 Business Profile
Foresee Pharmaceuticals Co., Ltd., clinical-stage pharmaceutical company, engages in the development and commercialization of drugs in Taiwan and Europe. The company's stabilized injectable formulation pipeline includes FP-001, which completed Phase III clinical study for the treatment of advanced stage prostate cancer; FP-004 that is in preclinical stage to treat opioids use disorder; FP-011 and FP-014, a long-acting sustained release dosage form for the treatment of breast cancer/prostate cancer; FP-015, for the treatment of neurological diseases; and FP-002 for the treatment of acromegaly, as well as FP-008 for the treatment of diabetic retinopathy. Its new chemical entity pipeline products consists of FP-020 to treat alport syndrome; FP-025, a selective matrix metalloproteinase-12 inhibitor, which is in Phase II clinical trial for the treatment of asthama, chronic obstructive pulmonary diseases, and emphysema or sarcoidosis; and FP-045, a small molecule mitochondrial aldehyde dehydrogenase 2 that completed Phase I clinical study for the treatment of peripheral arterial disease, fanconi anemia, and cardiorenal metabolic diseases. The company's strategic partners include Pierre Fabre Medicament Production and ScinoPharm. Foresee Pharmaceuticals Co., Ltd. was founded in 2013 and is headquartered in Taipei, Taiwan. Address:
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service

